Clustering of cardiovascular risk factors in rheumatoid arthritis: The rationale for using statins

Clinical and Experimental Rheumatology

Volumn 25, Issue 1, 2007, Pages 102-111

  Gazi, Irene F ^a   Boumpas, Dimitri T ^b   Mikhailidis, Dimitri P ^a   Ganotakis, Emmanuel S ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Atherosclerosis endothelial dysfunction; Cardiovascular disease; Dyslipidaemia; Inflammation; Rheumatoid arthritis; Statins

Indexed keywords

ANTIRHEUMATIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FLUINDOSTATIN; FOLIC ACID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INFLIXIMAB; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SIMVASTATIN;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CLUSTER ANALYSIS; COMORBIDITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; GENETIC RISK; GLUCOSE METABOLISM; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; KIDNEY AMYLOIDOSIS; LIPID ANALYSIS; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; MORALITY; NEOVASCULARIZATION (PATHOLOGY); NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; VASCULAR DISEASE;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 33947579832     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (200)

1. DROSOS AA: Epidemiology of rheumatoid arthritis. Autoimmune Rev 2004; 3 (Suppl. 1): S20-S2.
2. ALAMANOS Y, DROSOS AA: Epidemiology of adult rheumatoid arthritis. Autoimmune Rev 2005; 4: 130-6.
3. KAPLAN MJ: Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 289-97.
4. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
5. GOODSON N: Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 115-20.
6. KVALVIK AG, JONES MA, SYMMONS DP: Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29-37.
7. GERLI R, GOODSON NJ: Cardiovascular involvement in rheumatoid arthritis. Lupus 2005; 14: 679-82.
8. Van DOORNUM S, McCOLL G, WICKS IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-73.
9. HELIOVAARA M, AHO K, KNEKT P et al.: Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis 1995; 54: 811-4.
10. LINDQVIST E, EBERHARDT K: Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999; 58: 11-4.
11. KROOT EJA, van LEEUWEN MA, van RIJSWIJK MH et al.: No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000; 59: 954-8.
12. WARD MM: Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 2001; 44: 1467-9.
13. WOLFE F, MITCHELL DM, SIBLEY JT, FRIES JF: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
14. KVALVIK AG: Mortality in rheumatoid arthritis. Rheumatol Eur 1996; 25: 9-14.
15. SATTAR N, McINNES IB: Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92.
16. GOODSON NJ, SOLOMON DH: The cardiovascular manifestations of rheumatic diseases. Curr Opin Rheumatol 2006; 18: 135-40.
17. BACON PA, STEVENS RJ, CARRUTHERS DM, YOUNG SP, KITAS GD: Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmune Rev 2002; 1: 338-47.
18. BACON PA, TOWNEND JN: Nails in the coffin: Increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2707-10.
19. MYLLYKANGAS-LUOSUJARVI R, AHO K, KAUTIAINEN H, ISOMAKI H: Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995; 22: 1065-7.
20. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Cardiovascular death in rheumatoid arthritis. A population-based study. Arthritis Res 2005; 52: 722-32.
21. GOODSON N, MARKS J, LUNT M, SYMMONS D: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-601.
22. GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8.
23. WALLBERG-JONSSON S, OHMAN ML, DAHLQVIST SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
24. SYMMONS DP, JONES MA, SCOTT DL, PRIOR P: Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072-7.
25. GOODSON NJ, WILES NJ, LUNT M et al.: Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010-9.
26. SOLOMON DH, KARLSON EW, RIMM B et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
27. JACOBSSON LT, KNOWLER WC, PILLEMER S et al.: Rheumatoid arthritis and mortality. A longitudinal-study in Pima Indians. Arthritis Rheum 1993; 36: 1045-53.
28. TURESSON C, JACOBSSON LT: Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33: 65-72.
29. RIISE T, JACOBSEN BK, GRAN JT, HAGA HJ, ARNESEN E: Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 2001; 20: 123-7.
30. KRISHNAN E, LINGALA VB, SINGH G: Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004; 104: 1774-9.
31. MANZI S, CHESTER M WASKO M, MANZI S: Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000; 59: 321-5.
32. TURESSON C, JANENROS A, JACOBSSON L: Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community-based study. Ann Rheum Dis 2004; 63: 952-5.
33. VanDOORNUM S, KING B, BRAND C, SUNDARARAJAN V: Mortality rates following a first acute cardiovascular event: a comparison between rheumatoid arthritis patients and the general population. Arthritis Rheum 2005; 52: S702.
34. DOUGLAS KM, PACE AV, TREHARNE GJ et al.: Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65: 348-53.
35. BOOK C, SAXNE T, JACOBSSON LT: Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005; 32: 430-4.
36. GOODSON NJ, SYMMONS DP, SCOTT DG et al.: Baseline C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9.
37. MARADIT-KREMERS H, CROWSON CS, NICOLA PJ et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 402-11.
38. WARRINGTON K, KENT P, FRYE R et al.: Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case-control study. Arthritis Res Ther 2005; 7: 984-91.
39. CHUNG CP, OESER A, RAGGI P et al.: Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52: 3045-53.
40. KROOT EJ, VAN GESTEL AM, SWINKELS HL et al.: Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 2001; 28: 1511-7.
41. MIKULS TR, SAAG KG: Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 283-303.
42. WOLFE F, FREUNDLICH B, STRAUS WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40.
43. McENTEGART A, CAPELL HA, CRECAN D et al.: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-4.
44. WATSON DJ, RHODES T, GUESS HA: All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-202.
45. del RINCON ID, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
46. ERB N, PACE AV, DOUGLAS KM, BANKS MJ, KITAS GD: Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2004; 33: 293-9.
47. WISLOWSKA M, SYPULA S, KOWALIK I: Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 1998; 17: 369-77.
48. CHENG KS, MIKHAILIDIS DP, HAMILTON G, SEIFALIAN AM: A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002; 54: 528-38.
49. PARK YB, AHN CW, CHOI HK et al.: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46: 1714-9.
50. ROMAN MJ, MOELLER E, DAVIS A et al.: Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 249-56.
51. GROVER S, SINHA RP, SINGH U et al.: Subclinical atherosclerosis in rheumatoid arthritis in India. J Rheumatol 2006; 33: 244-7.
52. DASKALOPOULOU SS, DASKALOPOULOS ME, MIKHAILIDIS DP, LIAPIS CD: Detection of early atherosclerosis using the ultrasound parameters of the intima-media thickness of the common carotid artery in families with familial combined hyperlipidaemia. Int Angiol 2005; 24: 395.
53. GONZALEZ-JUANATEY C, LLORCA J, TESTA A et al.: Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-13.
54. LIANG KP, LIANG KV, MATTESON EL et al.: Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 2006; 54: 642-8.
55. DESSEIN PH, JOFFE BI: When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 2006; 33: 201-3.
56. FARZANEH-FAR A, ROMAN MJ: Accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Pract 2005; 59: 823-4.
57. RANTAPAA-DAHLQVIST S, WALLBERG-JONSSON S, DAHLEN G: Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 366-8.
58. PARK YB, LEE SK, LEE WK et al.: Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-4.
59. GEORGIADIS AN, PAPAVASILIOU EC, LOURIDA ES et al.: Atherogenic lipid profile is a feature of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006; 8: R82.
60. CHOI HK, SEEGER JD: Lipid profiles among US elderly with untreated rheumatoid arthritis- the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32: 2311-6.
61. ASANUMA Y, KAWAI S, AOSHIMA H, KABURAKI J, MIZUSHIMA Y: Serum lipoprotein (a) and apolipoprotein (a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 443-7.
62. TSELEPIS AD, ELISAF M, BESIS S et al.: Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum 1999; 42: 373-83.
63. LORBER M, AVIRAM M, LINN S, SCHARF Y, BROOK JG: Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol 1985; 24: 250-5.
64. SVENSON KL, LITHELL H, HALLGREN R, SELINUS I, VESSBY B: Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987; 147: 1912-6.
65. SITUNAYAKE RD, KITAS GD: Dyslipidaemia and rheumatoid arthritis. Ann Rheum Dis 1997; 56: 341-2.
66. HURT-CAMEJO E, PAREDES S, MASANA L et al.: Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001; 44: 2761-7.
67. PARK YB, CHOI HK, KIM MY et al.: Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113: 188-93.
68. MUNRO R, MORRISON E, McDONALD AG et al.: Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.
69. DESSEIN PH, JOFFE BI, STANWIX AE: Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4: R12.
70. WALLACE DJ, METZGER AL, STECHER VJ, TURNBULL BA, KERN PA: Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-6.
71. SVENSON KL, LITHELL H, HALLGREN R, VESSBY B: Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147: 1917-20.
72. KIORTSIS DN, MAVRIDIS AK, VASAKOS S, NIKAS SN, DROSOS AA: Effects of inflimixab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 921-3.
73. DAHLQVIST SR, ENGSTRAND S, BERGLIN E, JOHNSON O: Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term inflimixab therapy. Scand J Rheumatol 2006; 35: 107-11.
74. ETTINGER WH, KLINEFELTER HF, KWITEROVITCH PO: Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987; 63: 167-72.
75. BOERS M, NURMOHAMED MT, DOELMAN CJ et al.: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
76. RAYNAULD JP: Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids? J Rheumatol 1997; 24: 415-6.
77. CHAE CU, LEE RT, RIFAI N, RIDKER PM: Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
78. PERLSTEIN TS, LEE RT: Smoking, metalloproteinases, and vascular disease. Arterioscler Thromb Vasc Biol 2006; 26: 250-6.
79. PAPADOPOULOS NG, ALAMANOS Y, VOULGARI PV et al.: Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005; 23: 861-6.
80. MASDOTTIR B, JOHNSON T, MANFREDSDOTTIR V et al.: Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 1202-5.
81. WOLFE F: The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27: 630-7.
82. SILMAN AJ, NEWMAN J, MacGREGOR AJ: Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39: 732-5.
83. SOLOMON DH, CURRAN GC, RIMM EB, CANNUSCIO CC, KARLSON EW: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 3444-9.
84. GOODSON NJ, SILMAN AJ, PATTISON DJ et al.: Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 2004; 43: 731-6.
85. WALLBERG-JOHNSON S, JOHANSSON H, OHMAN ML, RANTAPAA-DAHLQVIST S: Extent of inflammation predicts cardiovascular disease and overall morality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71.
86. GERLI R, SHERER Y, VAUDO G et al.: Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005; 1051: 281-90.
87. DESSEIN PH, STANWIX AE, JOFFE BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4: R5.
88. HAKALA M, ILONEN J, REIJONEN H et al.: No association between rheumatoid arthritis and insulin dependent diabetes mellitus: an epidemiologic and immunogenetic study. J Rheumatol 1992; 19: 856-8.
89. GAZI I, LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF M: Metabolic syndrome: Clinical features leading to therapeutic strategies. Vasc Dis Prevent 2004; 1: 243-53.
90. GAZI I, TSIMIHODIMOS V, FILIPPATOS TD et al.: Concentration and relative distribution of LDL subfractions in patients with the metabolic syndrome defined according to the NCEP ATP III criteria. Metabolism 2006; 55: 885-91.
91. KARVOUNARIS SA, SIDIROPOULOS PI, PAPADAKIS JA et al.: Metabolic syndrome is common among middle- to older- age Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled study. Ann Rheum Dis 2006; in press.
92. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: METS-GREECE Collaborative Group. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004; 20: 1691-701.
93. GONZALEZ-JUANATEY C, TESTA A, GARCIA CASTELO A et al.: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-50.
94. SVENSON KL, LUNDQVIST G, WIDE L, HALLGREN R: Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. Metabolism 1987; 36: 944-8.
95. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
96. WALSMITH J, ROUBENOFF R: Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85: 89-99.
97. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3450-7.
98. VANDOORNUM S, JENNINGS GLR, WICKS IP: Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 2006; 184: 287-90.
99. CLARKE R, DALY L, ROBINSON K et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
100. ROUBENOFF R, DELLARIPA P, NADEAU MR et al.: Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997; 40: 718-22.
101. HAAGSMA CJ, BLOM HJ, van RIEL PL et al.: Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79-84.
102. MORGAN SL, BAGGOTT JE, LEE JY, ALARCON GS: Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-6.
103. ERB N, KITAS GD: Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients. Rheumatology 2001; 40: 715-6.
104. WALLBERG-JOHNSON S, CEDERFELT M, RANTAPAA-DAHLQVIST S: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000; 27: 71-5.
105. TSIARA S, ELISAF M, JAGROOP IA, MIKHAILIDIS DP: Platelets as predictors of vascular disease: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003; 9: 177-90.
106. MATSAGAS MI, GEROULAKOS G, MIKHAILIDIS DP: The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002; 16: 246-58.
107. BARRADAS MA, MIKHAILIDIS DP: Serotonin, histamine and platelets in vascular disease with special reference to peripheral vascular disease. Braz J Med Biol Res 1992; 25: 1063-76.
108. KNIJFF-DUTMER EA, KOERTS J, NIEUWLAND R, KALSBEEK-BATENBURG EM, van der LAAR MA: Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002; 46: 1498-503.
109. MILOVANOVIC M, NILSSON E, JAREMO P: Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 2004; 343: 237-40.
110. ICARDI A, ARAGHI P, CIABATTONI M et al.: Kidney involvement in rheumatoid arthritis (Abstract). Reumatismo 2003; 55: 76-85.
111. ELISAF M, MIKHAILIDIS DP: Statins and renal function. Angiology 2002; 53: 493-502.
112. KOSEKI Y, TERAI C, MORIGUCHI M, UESATO M, KAMATANI N: A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 327-31.
113. GAMBHIR JK, LALI P, MAZIERE JC: Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 1997; 30: 351-5.
114. OZKAN Y, YARDUM-AKAYDYN S, SEPICI A et al.: Oxidative stress in rheumatoid arthritis. Clin Rheumatol 2006; in press.
115. STEVENS RJ, DOUGLAS KM, SARATZIS AN, KITAS GD: Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005; 7: 1-24.
116. MACH F: Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events. Handb Exp Pharmacol 2005; 170: 697-722.
117. FAN J, WATANABE T: Inflammatory reactions in the pathogenesis of atherosclerosis. J ATHEROSCLER THROMB 2003; 10: 63-71.
118. PASCERI V, YEH ETH: A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-6.
119. SATTAR N, McCAREY DW, CAPELL H, McINNES IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
120. SNOW MH, MIKULS TR: Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 2005; 17: 234-41.
121. SHOENFELD Y, GERLI R, DORIA A et al.: Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.
122. del RINCON ID, WILLIAMS K, STERN MP et al.: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833-40
123. NAGATA-SAKURAI M, INABA M, GOTO H et al.: Inflammation and bone resorption as independent factors for accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 3061-7.
124. BRANEN L, HOVGAARD L, NITULESCU M et al.: Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 2137-42.
125. SALAZAR A, PINTO X, MANA J: Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 2001; 31: 1070-7.
126. KUMON Y, SUEHIRO T, IKEDA Y et al.: Influence of serum amyloid A protein on high-density lipoprotein in chronic inflammatory disease. Clin Biochem 1993; 26: 505-11.
127. STEINMETZ A, HOCKS G, SAILE R, PUCHOIS P, FRUCHART JC: Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989; 1006: 173-8.
128. BACON PA, RAZA K, BANKS MJ, TOWNEND J, KITAS GD: The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol 2002; 21: 1-17.
129. VALLANCE P, COLLIER J, BHAGAT K: Infection, inflammation and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 346: 1391-2.
130. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 115-7.
131. DESSEIN PH, JOFFE BI, SINGH S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634-R43.
132. PEDERSEN LM, NORDIN H, SVENSSON B, BLIDDAL H: Microalbuminuria in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 189-92.
133. VAUDO G, MARCHESI S, GERLI R et al.: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63: 31-5.
134. WONG M, TOH L, WILSON A et al.: Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48: 81-9.
135. HURLIMANN D, FORSTER A, NOLL G et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
136. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
137. RAZA K, THAMBYRAJAH J, TOWNEND JN et al.: Suppression of inflammation in primary vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000; 102: 1470-2.
138. HASKARD DO: Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol 2004; 33: 281-92.
139. MARTENS PB, GORONZY JJ, SCHAID D, WEYAND CM: Expansion of unusual CD4+ T-cells in severe rheumatoid arthritis. Arthritis Rheum 1997; 40: 1106-14.
140. - T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004; 109: 2744-8.
141. BOERS M, NURMOHAMED MT, DOELMAN CJ et al.: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
142. DESSEIN PH, JOFFE BI, STANWIX AE, CHRISTIAN B, VELLER M: Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31: 867-74.
143. GIROD JP, BROTMAN DJ: Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovasc Res 2004; 64: 217-26.
144. del RINCON ID, O'LEARY DH, HAAS RW, ESCALANTE A: Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3813-22.
145. JOHNSEN SP, LARSSON H, TARONE RE et al.: Risk of hospitalization for myocardial infarction among users of rofexocib, celexocib, and other NSAIDs. Arch Intern Med 2005; 165: 978-84.
146. GARCIA-RODRIGUEZ LA, GONZALEZ-PEREZ A: Long-term use of non-steroid anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Medicine 2005; 3: 17.
147. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
148. KEARNEY PM, BAIGENT C, GODWIN J et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8.
149. FISCHER LM, SCHLIENGER RG, MATTER CM, JICK H, MEIER CR: Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004; 164: 2472-6.
150. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFS F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
151. PRODANOWICH S, MA F, TAYLOR JR et al.: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
152. LANDEWE RBM, van den BORNE BEEM, BREEDVELD FC, DIJKMANS BAC: Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000; 355: 1616-7.
153. IZZEDINE H, LAUNAY-VACHER V, KARIE S et al.: Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005; 64: 315-9.
154. SVENDSEN KB, ELLINGSEN T, BECH JN et al.: Urinary excretion of a-GST and albumin in rheumatoid arthritis patients with methotrexate or other DMARDS alone or in combination with NSAIDs. Scand J Rheumatol 2005; 34: 34-9.
155. POPA C, NETEA MG, RADSTAKE T et al.: Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-5.
156. JACOBSSON LTH, TURESSON C, GULFE A et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-8.
157. GONZALEZ-JUANATEY C, LLORCA J, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150-3.
158. BERNATSKY S, HUDSON M, SUISSA S: Antirheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology 2005; 44: 677-80.
159. SWANBERG M, LIDMAN O, PADYUKOV L et al.: MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-94.
160. GRISAR J, ALETAHA D, STEINER CW et al.: Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111: 204-11.
161. JACOBSSON LT, TURESSON C, HANSON RL et al.: Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001; 44: 1170-6.
162. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
163. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet; 344: 1383-9.
164. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
165. ATHYROS VG, PAPAGEORGIOU AA, MERCOURIS BR et al.: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
166. ABELES AM, PILLINGER M: Statins as anti-inflammatory and immunomodulatory agents. A future in rheumatologic therapy? Arthritis Rheum 2006; 54: 393-407.
167. LIBEROPOULOS EN, ATHYROS VG, ELISAF MS, MIKHAILIDIS DP: Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: where are we now after the "treating to new targets" (TNT) trial? Hellenic J Cardiol 2005; 46: 161-4.
168. MILIONIS HJ, LIBEROPOULOS EN, ACHIMASTOS A, ELISAF MS, MIKHAILIDIS DP: Statins: another class of antihypertensive agents? J Hum Hypertens 2006; 20: 320-35.
169. LIBEROPOULOS EN, TSOULI S, MIKHAILIDIS DP, ELISAF MS: Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
170. MILIONIS HJ, GAZI IF, FILIPPATOS TD et al.: Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering? Angiology 2005; 56: 585-92.
171. KAKAFIKA AI, LIAMIS G, ELISAF M, MIKHAILIDIS DP: Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 2001; 17: 230-1.
172. KAKAFIKA AI, TSIMIHODIMOS V, ELISAF M: Effect of atorvastatin in serum uric acid levels. Atherosclerosis 2001; 158: 255.
173. ATHYROS VG, PAPAGEORGIOU AA, ELISAF M, MIKHAILIDIS DP: GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-7.
174. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
175. ATHYROS VG, ELISAF M, PAPAGEORGIOU AA et al.: GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidaemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
176. LIBEROPOULOS EN, MIKHAILIDIS DP, ATHYROS VG, ELISAF MS: The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis 2006; 47: 561.
177. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PINEIRO A et al.: High-grade C-reactive protein elevation correlates with accelerated atherogenesis
178. McCAREY DW, McINNES IB, MADHOK R et al.: Trial of atorvastatin in rheumatoid arthritis (TARA): a double-blind randomised placebo-controlled trial. Lancet 2004; 363: 2015-21.
179. KANDA H, HAMASAKI K, KUBO K et al.: Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 2002; 29: 2024-6.
180. TIKIZ C, UTUK O, PIRILDAR T et al.: Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005; 32: 2095-101.
181. LI J, LI YS, FANG CH et al.: Effects of Simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart 2006; 92: 529-30.
182. ABUD-MENDOZA C, de la FUENTE H, CUEVAS-ORTA E et al.: Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003; 12: 607-11.
183. BARSANTE MM, ROFFE E, YOKORO CM et al.: Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005; 516: 282-9.
184. YOKOTA K, MIYAZAKI T, HIRANO M, AKIYAMA Y, MIMURA T: Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-a in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2006; 33: 463-71.
185. LEUNG BP, SATTAR N, CRILLY A et al.: A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
186. FISCHETTI F, CARRETTA R, BOROTTO G et al.: Fluvastatin treatment inhibits leukocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004; 135: 186-93.
187. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
188. HERMANN F, FORSTER A, CHENEVARD R et al.: Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005; 45: 461-4.
189. TSIARA S, ELISAF M, MIKHAILIDIS DP: Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
190. BONETTI PO, LERMAN LO, NAPOLI C, LERMAN A: Statin effects beyond lipid-lowering - are they clinically relevant? Eur Heart J 2003; 24: 225-48.
191. VanDOORNUM S, McCOLL G, WICKS IP: Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1571-5.
192. McCAREY DW, SATTAR N, McINNES IB: Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 2005; 7: 55-61.
193. JURY EC, EHRENSTEIN MR: Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14: 192-6.
194. SOUBRIER M, ROUX C: Statins in rheumatology. Joint Bone Spine 2006; 73: 159-68.
195. KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulators. Nat Med 2000; 6: 1399-402.
196. PUCCETTI L, PASQUI AL, AUTERI A, BRUNI F: Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2004; 5: 121-6.
197. COSTENBADER KH, COBLYN JS: Stalin therapy in rheumatoid arthritis. South Med J 2005; 98: 534-40.
198. PLANA JC, JONES PH: The use of statins in acute coronary syndromes: the mechanisms behind the outcomes. Curr Atheroscler Rep 2001; 3: 355-64.
199. NAGASHIMA T, OKAZAKI H, MATSUNO H, MINOYA S: Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation. Arthritis Rheum 2006; 54: 579-86.
200. Can statins save the lives of rheumatoid arthritis patients? Available at: www.arc.org.uk/newsviews/press/jan2006/statins.htm. Assessed: July 6th, 2006.